Actualités

16-5-2012

Ablynx announces Q1 2012 business update

GHENT, Belgium, 16th May 2012 - Ablynx [Euronext Brussels: ABLX], the Belgian-based biopharmaceutical company focused on the discovery and development of Nanobodies® for the treatment of serious life-threatening diseases, today announced its business update for the three-month period ending 31st March 2012.
 

PDF-file [509kb]